NF-279
NF-279
NF-279 is a chemical compound known for its role as a selective antagonist of the P2X receptor, specifically targeting the P2X1 subtype. This compound has been studied for its potential therapeutic applications in various medical conditions, particularly those involving platelet aggregation and thrombosis.
Chemical Structure and Properties
NF-279 is a derivative of suramin, a well-known P2 receptor antagonist. The chemical structure of NF-279 allows it to selectively inhibit the P2X1 receptor, which is a ligand-gated ion channel activated by extracellular ATP. This selectivity is crucial for its potential use in medical applications where specific inhibition of P2X1 is desired.
Mechanism of Action
The primary mechanism of action of NF-279 involves its binding to the P2X1 receptor, thereby preventing the binding of ATP. This inhibition blocks the ion channel function of the receptor, which is responsible for calcium influx into cells. By inhibiting this pathway, NF-279 can reduce platelet aggregation, making it a potential candidate for antithrombotic therapy.
Therapeutic Applications
NF-279 has been investigated for its potential use in preventing thrombosis, a condition characterized by the formation of blood clots within blood vessels. By inhibiting P2X1 receptors on platelets, NF-279 can reduce platelet activation and aggregation, which are key steps in the formation of thrombi.
Research Studies
Several studies have demonstrated the efficacy of NF-279 in reducing platelet aggregation in vitro and in animal models. These studies suggest that NF-279 could be beneficial in conditions such as myocardial infarction, stroke, and other cardiovascular diseases where thrombosis plays a critical role.
Safety and Side Effects
As with any pharmacological agent, the safety profile of NF-279 is an important consideration. While preclinical studies have shown promising results, further research is needed to fully understand the potential side effects and toxicity of NF-279 in humans.
Future Directions
Ongoing research is focused on optimizing the pharmacokinetic properties of NF-279 to improve its efficacy and safety profile. Additionally, studies are being conducted to explore its potential use in other conditions where P2X1 receptor activity is implicated.
Also see
Pharmacomodulation | ||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Transform your life with W8MD's budget GLP-1 injections from $125.
W8MD offers a medical weight loss program to lose weight in Philadelphia. Our physician-supervised medical weight loss provides:
- Most insurances accepted or discounted self-pay rates. We will obtain insurance prior authorizations if needed.
- Generic GLP1 weight loss injections from $125 for the starting dose.
- Also offer prescription weight loss medications including Phentermine, Qsymia, Diethylpropion, Contrave etc.
NYC weight loss doctor appointments
Start your NYC weight loss journey today at our NYC medical weight loss and Philadelphia medical weight loss clinics.
- Call 718-946-5500 to lose weight in NYC or for medical weight loss in Philadelphia 215-676-2334.
- Tags:NYC medical weight loss, Philadelphia lose weight Zepbound NYC, Budget GLP1 weight loss injections, Wegovy Philadelphia, Wegovy NYC, Philadelphia medical weight loss, Brookly weight loss and Wegovy NYC
WikiMD's Wellness Encyclopedia |
Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD